Comparative survival curves for BLPD patients treated with anti-CD21 and anti-CD24 MoAbs to two risk factors: number of involved sites (A) and clonality (B). (A) Black line, paucivisceral BLPD survival (<4 sites involved) (n = 33); gray line, multivisceral BLPD survival (4 sites or more involved) (n = 26). Survival was better among paucivisceral than multivisceral BLPD patients as assessed by both in univariate analysis (P = .0007) and in multivariate analysis (RR = 1.4 per involved organ, P = .0002). (B) Black line, monoclonal BLPD survival (n = 28); gray line, oligoclonal BLPD survival (n = 26). The difference between the two groups is not statistically significant (P = .10).